Flupenthixol + Melitracen

Description

Introducing Flupenthixol + Melitracen Tablets by PharmAlliance International Labs

Welcome to PharmAlliance International Labs, where we are dedicated to pioneering healthcare solutions that enhance the well-being of individuals worldwide. Our Flupenthixol + Melitracen Tablets represent a significant advancement in the treatment of depressive disorders, offering a holistic approach to managing symptoms and restoring emotional balance. With a steadfast commitment to quality and patient-centered care, we strive to deliver products that empower individuals to reclaim their mental health and lead fulfilling lives.

Drug Classification:

Flupenthixol + Melitracen Tablets belong to the class of antidepressants, specifically combining the properties of a neuroleptic agent (flupenthixol) with those of a tricyclic antidepressant (melitracen). This unique combination harnesses synergistic effects to effectively alleviate symptoms associated with depressive disorders

Formulations:

Our Flupenthixol + Melitracen Tablets are formulated with precision, each tablet containing Flupentixol 0.5mg and Melitracen 10 mg. Presented in convenient oral tablet form, our product ensures ease of administration and optimal patient compliance. Each pack contains 100 tablets, providing an ample supply for continuous treatment.

Indications:

These tablets are indicated for the treatment of depressive disorders, encompassing conditions such as Major Depressive Disorder (MDD) and dysthymia. Flupenthixol + Melitracen Tablets effectively target symptoms including depressed mood, loss of interest, changes in appetite or weight, sleep disturbances, fatigue, and impaired concentration, among others.

Usage:

For optimal efficacy, Flupenthixol + Melitracen Tablets should be taken orally with water, preferably alongside food to mitigate gastrointestinal discomfort. Adherence to the prescribed dosage and dosing schedule, as directed by a healthcare professional, is imperative for achieving therapeutic benefits. Close monitoring of therapeutic response and potential adverse effects is recommended throughout the treatment duration.

Dosage:

The recommended starting dose is one tablet daily, with dosage adjustments made based on individual patient response and tolerability. The maximum daily dose should not exceed two tablets per day to minimize the risk of adverse effects while ensuring therapeutic efficacy.

Pharmacokinetics:

Upon oral administration, both flupenthixol and melitracen are readily absorbed and undergo extensive metabolism in the liver. Peak plasma concentrations are typically attained within 2 to 4 hours post-administration, with variable half-lives dictating their duration of action.

Pharmacodynamics:

Flupenthixol acts primarily by blocking dopamine D2 receptors, modulating dopaminergic neurotransmission, while melitracen functions as a selective serotonin reuptake inhibitor (SSRI), augmenting serotonin levels in the synaptic cleft. This synergistic mechanism of action contributes to mood improvement and symptom alleviation in depressive disorders.

Side Effects:

Common side effects may include drowsiness, dizziness, dry mouth, constipation, blurred vision, and weight gain. Less frequent but potentially severe side effects such as extrapyramidal symptoms, orthostatic hypotension, cardiac arrhythmias, and serotonin syndrome may occur. Prompt reporting of any new or worsening symptoms to healthcare providers is advised.

Trust in the efficacy and safety of Flupenthixol + Melitracen Tablets from PharmAlliance International Labs. Whether you are navigating depression or dysthymia, our product offers a dependable solution to alleviate symptoms and enhance your quality of life. For further information, please visit our website or consult with your healthcare provider.